ALCAM and prostate cancer: The Pb-Cre+;PtenL/L;CD166+/− and Pb-Cre+;PtenL/L;CD166−/− mouse models generated in this study, therefore, can be used to investigate the efficiency of CD166 - mediated drug delivery to prostate cancer initiating cells in vivo, especially during CRPC development.